Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.73 |
| ▸ | PKM | P14618 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.66 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | MET | P08581 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30610305 | 1.00 | ALDH1A1 (0.73) | ALDH1A1PKMMEN1KMT2APOLB | |
| SCHEMBL3537948 | 0.94 | ALDH1A1 (0.84) | ALDH1A1PKMMEN1KMT2APOLB | |
| SCHEMBL2360974 | 0.89 | ALDH1A1 (0.84) | ALDH1A1PKMMEN1KMT2APOLB | |
| SCHEMBL4033939 | 0.88 | ALDH1A1 (0.64) | ALDH1A1PKMMEN1KMT2APOLB | |
| SCHEMBL4026842 | 0.88 | ALDH1A1 (0.64) | ALDH1A1PKMMEN1KMT2APOLB | |
| SCHEMBL5347059 | 0.86 | ALDH1A1 (0.97) | ALDH1A1PKMMEN1KMT2APOLB | |
| SCHEMBL29432508 | 0.85 | ALDH1A1 (0.73) | ALDH1A1PKMMEN1KMT2APOLB | |
| SCHEMBL28137833 | 0.84 | ALDH1A1 (1.00) | ALDH1A1PKMMEN1KMT2APOLB | |
| SCHEMBL2448409 | 0.83 | ALDH1A1 (0.55) | ALDH1A1PKMMEN1KMT2APOLB | |
| SCHEMBL2448445 | 0.83 | ALDH1A1 (0.55) | ALDH1A1PKMMEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546397-B2 | DNA methylation inhibitors | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-10-01 | — | — | US | disclosed |
| US-8546397-B2 | DNA methylation inhibitors | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-10-01 | — | — | US | disclosed |
| US-20120157465-A1 | DNA METHYLATION INHIBITORS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2012-06-21 | — | — | US | disclosed |
| US-20080058312-A1 | Modulators of hepatocyte growth factor/c-Met activity | ANGION BIOMEDICA CORPORATION (US) | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157465-A1 | DNA METHYLATION INHIBITORS | MECP2, DNMT1, DNMT3B | ALDH1A1 2789/4885PKM 4235/4885MEN1 3018/4885 |
| US-20080058312-A1 | Modulators of hepatocyte growth factor/c-Met activity | HGF, MET, HDGF | ALDH1A1 823/4885PKM 2938/4885MEN1 913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.